These findings are consistent with an increased SR-BI expression in Leydig cell tumors, nasopharyngeal carcinoma, prostate cancers, and some breast cell lines such as HBL-100 and MCF-7 [105,106,107]. Here, SCARB1 is linked to nasopharyngeal carcinoma.